2013 proved an eventful year for proteomics as the field saw milestones ranging from the release of long-awaited clinical tests to key regulatory clearances to noteworthy new instrument launches.

In particular, the move of mass spec into the clinic continued to gain steam, as both diagnostic firms and tool vendors notched major wins in pushing clinical products to market.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.